ChemoCentryx Stock

ChemoCentryx Debt 2024

ChemoCentryx Debt

-26.34 USD

Ticker

CCXI

ISIN

US16383L1061

WKN

A0NBM2

In 2024, ChemoCentryx's total debt was -26.34 USD, a 0% change from the 0 USD total debt recorded in the previous year.

ChemoCentryx Aktienanalyse

What does ChemoCentryx do?

ChemoCentryx Inc. was founded in 1997 and is based in Mountain View, California. The company specializes in the development of medications for rare autoimmune diseases, cancer, and inflammation. Since its founding, ChemoCentryx Inc. has developed a variety of drug candidates, some of which are in clinical phases or as finished products. The business model of ChemoCentryx Inc. is based on the discovery and development of medications targeting chemokines and chemokine receptors. This technology allows for the regulation and control of inflammatory processes. The company also utilizes its proprietary Janus kinase inhibitors (JAK inhibitors) for the treatment of inflammatory diseases. ChemoCentryx Inc. has several business areas. The primary area is the research and development of medications that can be used as candidates against inflammatory, cancer, autoimmune, and fibrosis diseases. The second significant area is collaboration with international partners in the research and development of these medications. The company has also developed specialized tools and technologies to optimize its drug development processes. These techniques include high-throughput screening and X-ray crystallography technologies, as well as biomarker-based diagnostics. One important product of ChemoCentryx Inc. is Avacopan, an oral medication used in the treatment of ANCA-associated vasculitic diseases such as granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA). Avacopan is a selective antagonist of the C5a receptor, which plays a central role in the inflammatory response. Clinical studies on the efficacy and safety of Avacopan have yielded promising results, and the medication has received Breakthrough Therapy Designation status from the US FDA. Additionally, ChemoCentryx Inc. has successfully identified candidates for the treatment of atopic dermatitis, lupus nephritis, and Crohn's disease. These products are still in the clinical development phase and have great potential to significantly improve the lives of patients suffering from these conditions. Overall, ChemoCentryx Inc. has made significant progress in the discovery and development of drugs that can combat inflammation and other chronic diseases. The company is well-positioned to expand its pipeline and bring additional breakthrough products to market that will play a crucial role in treating diseases that have been difficult to treat in the past. ChemoCentryx ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Debt Details

Understanding ChemoCentryx's Debt Structure

ChemoCentryx's total debt refers to the cumulative financial obligations the company owes to external parties. This can include short-term and long-term borrowings, bonds, loans, and other financial instruments. Assessing the company's debt levels is crucial for evaluating its financial health, risk profile, and ability to fund operations and expansions.

Year-to-Year Comparison

Analyzing ChemoCentryx's debt structure over the years provides insights into the firm’s financial strategy and stability. A reduction in debt can indicate financial strength and operational efficiency, while an increase may signal growth investments or potential financial challenges ahead.

Impact on Investments

Investors pay close attention to ChemoCentryx’s debt levels as they can influence the company’s risk and return profiles. Excessive debt can lead to financial strain, while moderate and well-managed debt can be a catalyst for growth and expansion, making it a critical aspect of investment evaluations.

Interpreting Debt Fluctuations

Shifts in ChemoCentryx’s debt levels can be attributed to various operational and strategic factors. An increase in debt might be geared towards funding expansion projects or enhancing operational capacity, while a decrease may indicate profit realizations or an approach to minimize financial risk and leverage.

Frequently Asked Questions about ChemoCentryx stock

What is the debt of ChemoCentryx this year?

ChemoCentryx has a debt level of -26.34 USD this year.

What was the debt of ChemoCentryx compared to the previous year?

The debt of ChemoCentryx has increased by 0% compared to the previous year dropped.

What are the consequences of high debt for investors in ChemoCentryx?

High debt can pose a risk for investors of ChemoCentryx, as it can weaken the company's financial position and hinder its ability to fulfill its obligations.

What are the consequences of low debt for investors of ChemoCentryx?

Low debt means that ChemoCentryx has a strong financial position and is able to fulfill its obligations without overburdening its finances.

How does an increase in debt from ChemoCentryx affect the company?

An increase in debt of ChemoCentryx can adversely affect the financial condition of the company and result in a higher burden on its finances.

How does a reduction of debt of ChemoCentryx affect the company?

A reduction in debt of ChemoCentryx can strengthen the company's financial position and improve its ability to meet its financial obligations.

What are some factors that influence the debt of ChemoCentryx?

Some factors that can influence the debt of ChemoCentryx include investments, acquisitions, operating costs, and revenue development.

Why are the debts of ChemoCentryx so important for investors?

The debts of ChemoCentryx are important for investors as they serve as an indicator of the company's financial stability. It provides investors with information on how the company fulfills its financial obligations.

What strategic measures can ChemoCentryx take to change the debt?

To change the debt, ChemoCentryx can take measures such as cost savings, increasing revenue, selling assets, making investments, or forming partnerships. It is important for the company to conduct a thorough review of its financial situation to determine the best strategic actions to change its debt.

How much dividend does ChemoCentryx pay?

Over the past 12 months, ChemoCentryx paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, ChemoCentryx is expected to pay a dividend of 0 USD.

What is the dividend yield of ChemoCentryx?

The current dividend yield of ChemoCentryx is .

When does ChemoCentryx pay dividends?

ChemoCentryx pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of ChemoCentryx?

ChemoCentryx paid dividends every year for the past 0 years.

What is the dividend of ChemoCentryx?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is ChemoCentryx located?

ChemoCentryx is assigned to the 'Health' sector.

Wann musste ich die Aktien von ChemoCentryx kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of ChemoCentryx from 11/1/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 11/1/2024.

When did ChemoCentryx pay the last dividend?

The last dividend was paid out on 11/1/2024.

What was the dividend of ChemoCentryx in the year 2023?

In the year 2023, ChemoCentryx distributed 0 USD as dividends.

In which currency does ChemoCentryx pay out the dividend?

The dividends of ChemoCentryx are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

The ChemoCentryx stock can be added to a savings plan with the following providers: Trade Republic

Andere Kennzahlen von ChemoCentryx

Our stock analysis for ChemoCentryx Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of ChemoCentryx Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.